Φορτώνει......

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

METHOD: The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study....

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Nature Publishing Group 2011
Θέματα:	Clinical Study
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3172912/ https://ncbi.nlm.nih.gov/pubmed/21750549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.257
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Παρόμοια τεκμήρια